Across TCGA pan-cancer cohorts, GATA2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GATA2 data layer compared with 25 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GATA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GATA2 expression acts as an unfavorable survival marker.
UCEC are the cancer types where GATA2 mass-spec protein most reproducibly stratifies survival.